Serum ischaemia-modified albumin increases in critical lower limb ischaemia

Gunduz, Abdülkadir; Menteşe, Ahmet; Türedi, Süleyman; Karahan, Süleyman Caner; Menteşe, Ümit; Eroğlu, Oğuz; Turkmen, Süha; Turan, İbrahim; Ucar, Utku; Russell, Robert M; Balaban, F.

doi:10.1136/emj.2007.051292

Cited by 33 publications

(22 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Modifications that alter the binding capacity of albumin for cobalt may arise during ischemiareperfusion as a result of acidosis, reduced oxygen tension, and the generation of free radicals. Recent research has shown that a variety of conditions may raise ischemia-modified albumin levels, including pulmonary embolism, mesenteric ischemia, peripheral arterial occlusion, deep venous thrombosis, and stroke, and that ischemia-modified albumin may be a diagnostic biomarker for these conditions (4)(5)(6)(7)(8).…”

mentioning

confidence: 99%

Investigation of the possibility of using ischemia-modified albumin in testicular torsion: an experimental study

Kutlu

Menteşe

Turkmen

et al. 2011

Fertility and Sterility

View full text Add to dashboard Cite

mentioning

confidence: 99%

Investigation of the possibility of using ischemia-modified albumin in testicular torsion: an experimental study

Kutlu

Menteşe

Turkmen

et al. 2011

Fertility and Sterility

View full text Add to dashboard Cite

“…Recently, significant increases in IMA levels have been reported in various ischemic conditions, such as pulmonary infarct, critical lower limb ischemia and cerebrovascular disease, suggesting that IMA may be useful as a diagnostic marker for these conditions [6][7][8] . IMA has been shown to be elevated in patients after percutaneous coronary intervention as a result of ischemia-reperfusion injury [9] .…”

mentioning

confidence: 99%

Ischemia-Modified Albumin Reduction after Coronary Bypass Surgery Is Associated with the Cardioprotective Efficacy of Cold-Blood Cardioplegia Enriched with N-Acetylcysteine: A Preliminary Study

Karahan¹,

Koramaz²,

Altun³

et al. 2009

Eur Surg Res

View full text Add to dashboard Cite

Background: The aims of this preliminary study were to determine the alteration of serum ischemia-modified albumin (IMA) levels and to investigate whether IMA may be used as an indicator of the cardioprotective efficacy of N-acetylcysteine (NAC) in patients undergoing coronary bypass grafting (CABG). Patients and Methods: Forty-four patients were randomized into one of two groups on the basis of cardioplegic strategies, either cold-blood cardioplegia enriched with NAC (50 mg/kg) or cold-blood cardioplegia alone. Serum IMA, cardiac troponin T (cTnT) and malondialdehyde (MDA) levels determined in NAC-enriched patients before and after CABG were compared with those of the NAC-free group. The albumin cobalt binding assay was used for IMA determination. Results: Serum IMA levels were significantly elevated after cross-clamping and peaked at 6 h after reperfusion in the two groups. In NAC-enriched patients, IMA levels determined 6, 12, 24 and 48 h after reperfusion were significantly lower than those of the NAC-free group (p ≤ 0.001, p < 0.001, p < 0.001 and p < 0.001, respectively). IMA returned to baseline 24 h after reperfusion differently from cTnT and MDA in the NAC-enriched group. Conclusions: IMA may be used as not only an indicator of myocardial ischemia-reperfusion injury, but also as a useful indicator of the cardioprotective effect of NAC in CABG.

show abstract

“…Serum IMA is elevated in cardiac ischaemia,9 10 ischaemic stroke,11 bowel infarction12 and limb ischaemia 13. IMA levels were also found to be higher in case-control studies of DVT14 and PE15 patients in the ED.…”

Section: Introductionmentioning

confidence: 92%